FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 360:313 January 15, 2009 Number 3 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

(Basic and Clinical Oncology. 35.) Edited by Gertjan J.L. Kaspers, Bertrand Coiffier, Michael C. Heinrich, and Elihu Estey. 598 pp., illustrated. New York, Informa Healthcare, 2008. $279.95. ISBN 978-0-8493-5083-2.

Research on the biologic basis of leukemias and lymphomas has revealed new molecular entities with distinctive genetic and epigenetic abnormalities. Correct diagnosis of these disorders affects their clinical management because they involve genetic markers that can be used to stratify patients to risk-adapted therapies. The therapeutic relevance of compounds aimed at distinct molecular targets in cancer cells has become clear since the successful use of imatinib in the treatment of chronic myelogenous leukemia.

Innovative Leukemia and Lymphoma Therapy is a complete and up-to-date synopsis of the new targeted treatments that are being developed for leukemias and lymphomas. All the chapters . . . [Full Text of this Article]

HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.